Advertisement

Topics

Latest Cancer NewsRSS

08:09 EDT 23rd August 2017 | BioPortfolio

Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders

- Annual Meeting Rescheduled for October 5, 2017 - Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced that its 2017 Annual Meeting of S...

Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma

- First ACTR Combination Therapy Under Unum’s Collaboration with Seattle Genetics – - Company Plans to Initiate Patient Dosing in a Multi-center, Phase 1 Trial in Q1 2018 – Unum Therapeutics Inc., a clinical stage

Nativis to Present at 19th Annual Rodman & Renshaw Global Investment Conference

Updates to include partnerships, clinical progress and plans for 2018 Nativis, Inc., a clinical stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced that it will be featured as a presenting company at the

HemaCare Will Attend Annual CAR-TCR Conference in Boston

HemaCare Corporation (OTCBB: HEMA), announced today that it will be attending the annual CAR-TCR conference September 5-8, 2017, in Boston, MA. The conference is focused on the development and commercialization of cell therapy that uses the immune system to fight cancer and other diseases. CAR-TCR stands for Chimeric Antigen Receptor (CAR) and T Cell Recep...

Golden Biotechnology Corp 4132 Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryGolden Biotechnology Corp Golden Biotech is a biotechnology company that offers drug development programs. The company develops and commercializes drugs and herbal supplements to prevent and treat several cancer diseases. It discovers new drugs for antiatherosclerosis and anticancer from the screening platforms. Golden Biotech offers products which include liverty, zsaino, rasle, and umooze...

Cancer Survival Prediction Tool Developed by University of Leicester Researchers

Unique online application helps to interpret statistics on cancer survival Researchers from the University of Leicester have developed an online tool which presents a variety of measures that quantify the survival of patients with cancer from different perspectives. The ‘InterPreT Cancer Survival’ tool, which has been developed by University of Leicester PhD student Sarwar Islam...

Registration Now Open – 2017 Chabner Colloquium

Registration is now open for the Society for Translational Oncology (STO) Chabner Colloquium: Answering the Big Questions in Cancer Research & 2017 STO Annual Meeting. This live symposium is jointly provided by the Massachusetts General Hospital Cancer Center and STO, in partnership with The Oncologist, STO's official journal. Durham, NC (PRWEB) August 23, 2017 Registration is now open fo...

Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea

- Deal provides for up to $3,000,000 in upfront and milestone payments & 23% royalties - Agreement includes distributor’s right of first refusal to distribute Namodenoson for other indications including NASH Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipel

Mekinist Drug Insights, 2017 [Report Updated: 10072017] Prices from USD $1000

DelveInsight's pharmaceuticals report, Mekinist Drug Insights, 2017 highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Mekinist covering the historical global sales and also provides the Mekinist sales estimation during the forecasted period 20172019. The report also covers ...

China NT Pharma Group Co Ltd 1011 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25072017] Prices from USD $250

SummaryChina NT Pharma Group Co Ltd NT Pharma is a technologybased pharmaceutical company, which researches, develops, manufactures, and distributes branded and generic pharmaceuticals. The company also promotes and distributes drugs manufactured by third parties. It develops drugs for indications such as cancer; central nervous system disorders; orthopedics; hepatopathy and respiratory disorders....

Alvogen Korea Co Ltd 002250 Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryAlvogen Korea Co Ltd Alvogen, formerly KunWha Pharmaceutical Co Ltd, a subsidiary of Alvogen Inc is a manufacturer of prescription pharmaceuticals for use in various therapeutic areas. The company offers products in various therapeutic such as cardiology, nephrology and urology. It offers antiobesity treatment products, therapeutic drugs and incrementally modified drugs. Alvogen's antiobesi...

amcure Announces Formation of Inaugural Scientific Advisory Board

amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, today announced the appointment of a distinguished group of oncology specialists and academic leaders to the company’s Scientific Advisory Board (SAB). The multinational group of experts will serve as a strategic resource to amcure as it continues to advance its lead compo...

EnGeneIC Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27072017] Prices from USD $250

SummaryEnGeneIC Ltd EnGeneIC is a biopharmaceutical company that develops drugs and other therapeutic molecules. The company develops nanocell platform used as a platform for the creation of custom therapies for cancer. Its cytoimmunotherapy platform releases concentrations of RNAinterference molecules, chemotherapeutic agents, and molecularly targeted drugs into targeted tumor cells. EnGeneIC's t...

Macrophage Pharma Limited Extends Series A Round to Include New Investor Merck Ventures

WINDSOR, England, August 23, 2017 /PRNewswire/ -- Macrophage Pharma Limited ('MPL') the immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), announced today that it has raised additional funding from Merck Ventures to complete the Series A Financing announced in January 2017. Merck Ventures joins the existing investor synd...

Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion

NEW YORK, August 23, 2017 /PRNewswire/ -- If you want a Stock Review on MACK, MNKD, NDRM, or CLSN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Tuesday, August 22, 2017, the NASDAQ Composite ended the trading session at 6,297.48, up 1.36%; the Dow Jones Industrial Average edged 0.90% higher, to finish at 21,899.89; and the S&...

Excelera® Specialty Pharmacy Network Joins Merck’s Commitment to Hepatitis C

ExceleraRx Corp. has joined efforts with Merck to improve patient care for approximately 3.5 million people in the United States who live with chronic HCV infection. Excelera specialty pharmacy network members will have access to Hep C products including Zepatier®. Minneapolis, MN (PRWEB) August 23, 2017 The Excelera network consists of point-of-care specialty pharmacies owned by health syst...

Discovery Life Sciences announces major expansion of its Clinical Research Network to support Novel Cancer, Hepatitis, HIV, and Women's Health Test Development with Complex Human Biospecimens.

LOS OSOS, Calif., Aug. 23, 2017 /PRNewswire/ -- Discovery Life Sciences - a Life Sciences Industry leader in providing ethically obtained complex clinical research sample sets, diagnostic specimens and Human Biofluids announced today a significant expansion of its Discovery Partners™ Clinical Research network that identifies Patients for high value, next-generation Medical Device clinical trials...

Mycenax Biotech Inc 4726 Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryMycenax Biotech Inc Mycenax is a biopharmaceutical company that develops and manufactures pharmaceutical formulations. The company's pipeline portfolio encompasses investigational candidates targeted at the treatment of plaque psoriasis, glioblastoma, asthma, adult crohn's Disease, and breast cancer and indications for treatment of patients undergoing chemotherapy. It offers services includ...

Globeimmune Inc GBIM Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryGlobeimmune Inc Globeimmune is a biopharmaceutical company that manufactures and distributes therapeutic products for cancer and infectious diseases. It offers products for infectious disease and oncology. The company's oncology products include GI4000, GI6207 and GI6301. Globeimmune's infectious disease products include GS4774, GI19000, GI2010 and GI18000. The company's GI6207 targets carc...

Columbia China Starts Construction on $150M Hospital in Jiaxing, China

Columbia China, a 50-50 joint venture between Seattle’s Columbia Pacific Management and Singapore investment company Temasek, started construction today on a 500-bed multi-specialty hospital in Zhejiang Province. Columbia Jiaxing Hospital, which is set to open in 2019, will cost US $150 million (RMB 1 billion) to construct and is Columbia China...

Nordic Nanovector ASA - Results for Second Quarter and First Half Year 2017

OSLO, Norway, August 23, 2017 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces results for the second quarter and half year of 2017. A presentation by the company's senior management team will take place today at 8:30 a.m. CEST in Oslo - details below. Nordic Nanovector reported continued solid operational progress during the second quarter, with very encouraging clinical r...

GlaxoSmithKline Plc GSK Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27072017] Prices from USD $250

SummaryGlaxoSmithKline Plc GSK is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immunoinflammation and rare diseases. The company offers overthecounter OTC products for pain rel...

Go Green Processing Says Medical Marijuana Industry Maturing Through Established Business Channels

PHOENIX, Aug. 22, 2017 /PRNewswire/ -- Go Green Processing — provider of merchants services to the cannabis industry as well as other industries — reports on the state of the medical marijuana industry, its maturation through established marketplaces and the obstacles it faces ahead. Marijuana / Industrial Hemp and its growing industry have received quite a broad range of re...

Novacyt SA ALNOV Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryNovacyt SA Novacyt is a medical device company that develops and markets medical cytology solutions. The company offers consumable products and automated instruments. It offers consumable products such as vials, sedimentation system, and novastick solution. Novacyt also provides automated analysis instruments such as NPS 25 and NPS 50. The company offers cytology services, which are used in...

What's Next for Bristol-Myers Squibb After Its Opdivo Setback?

Mixed results for a study with Opdivo in treating first-line kidney cancer give reasons for concern. But how worried should investors really be? reported its checkpoint inhibitor Imfinzi failed to improve progression-free survival in a late-stage study targeting lung cancer.

Quick Search
Advertisement
 

review and buy Cancer market research data and corporate reports here